Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI vs FP/SAL Pulmonary Function Profile in COPD
NCT01323621Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Primary completion
- Jan 2012
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84. Started Mar 2011; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01323621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01323621.